Merck & Co. (MRK) : Regent Investment Management reduced its stake in Merck & Co. by 2.68% during the most recent quarter end. The investment management company now holds a total of 39,103 shares of Merck & Co. which is valued at $2,307,859 after selling 1,075 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Jul 15, 2016.Merck & Co. makes up approximately 1.21% of Regent Investment Management’s portfolio.
Other Hedge Funds, Including , Deroy Devereaux Private Investment Counsel Inc boosted its stake in MRK in the latest quarter, The investment management firm added 4,633 additional shares and now holds a total of 248,479 shares of Merck & Co. which is valued at $14,796,924. Merck & Co. makes up approx 1.91% of Deroy Devereaux Private Investment Counsel Inc’s portfolio.Davenport Co boosted its stake in MRK in the latest quarter, The investment management firm added 9,414 additional shares and now holds a total of 1,651,820 shares of Merck & Co. which is valued at $98,365,881. Merck & Co. makes up approx 1.46% of Davenport Co’s portfolio.Palisade Asset Management reduced its stake in MRK by selling 250 shares or 1.21% in the most recent quarter. The Hedge Fund company now holds 20,448 shares of MRK which is valued at $1,217,678. Merck & Co. makes up approx 0.23% of Palisade Asset Management’s portfolio.Curian Capital reduced its stake in MRK by selling 250,108 shares or 67.29% in the most recent quarter. The Hedge Fund company now holds 121,579 shares of MRK which is valued at $7,215,714. Merck & Co. makes up approx 0.52% of Curian Capital’s portfolio.
Merck & Co. closed down -0.61 points or -1.02% at $59.02 with 87,69,171 shares getting traded on Monday. Post opening the session at $59, the shares hit an intraday low of $58.715 and an intraday high of $59.49 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.